Abexinostat - CAS 783355-60-2
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Abexinostat
Catalog Number:
783355-60-2
Synonyms:
CRA-024781; CRA 024781; CRA024781; PCI-24781; PCI24781; PCI 24781; Abexinostat.
CAS Number:
783355-60-2
Description:
Abexinostat, also known as PCI-24781 or CRA-024781, is novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Abexinostat inhibits several isoforms of HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling.
COA:
Inquire
MSDS:
Inquire
Targets:
HDAC
Chemical Structure
CAS 783355-60-2 Abexinostat

Related HDAC Products


CAS 929016-96-6 Pracinostat

Pracinostat
(CAS: 929016-96-6)

Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits ...

CAS 950762-95-5 PCI-34051

PCI-34051
(CAS: 950762-95-5)

PCI-34051 is a potent, histone deacetylase 8 (HDAC8)-specific inhibitor with >200-fold selectivity over the other HDAC isoforms. PCI-34051 induces caspase-depen...

CAS 1252003-15-8 Tubastatin A

Tubastatin A
(CAS: 1252003-15-8)

Tubastatin A is selective at all isozymes except HDAC8 and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately...

CAS 1045792-66-2 CAY10603

CAY10603
(CAS: 1045792-66-2)

CAY10603 is a potent and selective inhibitor of HDAC6 with IC50 of 2 pM, as compared with 271, 252, 0.42, 6851, and 90.7 nM for HDAC1, 2, 3, 8, and 10, respecti...

CAS 149647-78-9 Vorinostat

Vorinostat
(CAS: 149647-78-9)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM.

CAS 251456-60-7 M344

M344
(CAS: 251456-60-7)

M344 is a potent HDAC inhibitor, which can also induced expression of the pro-apoptotic genes, Puma and Bax, together with the morphological features of apoptos...

ST7612AA1
(CAS: 1428535-92-5)

ST7612AA1 is a potent Histone deacetylase (HDCA) inhibitor. It showed an in vitro activity in the nanomolar range associated with a remarkable in vivo antitumor...

UF010
(CAS: 537672-41-6)

UF-010 is a Class I HDAC inhibitor, inhibiting proliferation of a range of cancer cell lines.

CAS 1215493-56-3 RG2833

RG2833
(CAS: 1215493-56-3)

RGFP 109 is a histone deacetylase (HDAC) inhibitor that has shown to reverse FXN gene silencing in short-term studies of Friedreich ataxia (FRDA) patient cells.

CAS 864814-88-0 Resminostat

Resminostat
(CAS: 864814-88-0)

Resminostat is an orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs ...

ACY-775
(CAS: 1375466-18-4)

ACY-775 is a selective Histone Deacetylase 6 (HDAC6) inhbiitor with low nanomolar potency and a selectivity of 60- to 1500-fold over class I HDACs. ACY-775 has...

CAS 1622921-15-6 Remodelin

Remodelin
(CAS: 1622921-15-6)

Remodelin, via inhibition of NAT10, mediates nuclear shape rescue of LMNA depleted cells by microtubule reorganization, and improves nuclear shape and fitness o...

CAS 1310693-92-5 Tubastatin A HCl salt

Tubastatin A HCl salt
(CAS: 1310693-92-5)

Tubastatin A is a potent and selective HDAC6 inhibitor. Tubastatin A was substantially more selective than the known HDAC6 inhibitor Tubacin at all isozymes exc...

CAS 1418033-25-6 LMK-235

LMK-235
(CAS: 1418033-25-6)

LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor. LMK-235 demonstrates activity against chemoresistant cancer cell lines in an MTT assa...

CAS 156-54-7 Sodium butyrate

Sodium butyrate
(CAS: 156-54-7)

Sodium butyrate is the sodium salt of butyric acid, used in the culture of mammalian cells.

CAS 128517-07-7 Romidepsin

Romidepsin
(CAS: 128517-07-7)

Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM ...

CAS 112522-64-2 Tacedinaline

Tacedinaline
(CAS: 112522-64-2)

Tacedinaline, also known as CI-944, is an orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits his...

CAS 1069-66-5 Valproic acid sodium salt (Sodium valproate)

Valproic acid sodium salt (Sodium valpro
(CAS: 1069-66-5)

Valproic acid is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention o...

CAS 99-66-1 Valproic acid

Valproic acid
(CAS: 99-66-1)

Valproic acid is an inhibitor of histone deacetylase (HDAC) inhibitor, which has an anticancer effect. It is a branched short-chain fatty acid. It is previously...

CAS 937039-45-7 TC-H 106

TC-H 106
(CAS: 937039-45-7)

TC-H 106 is a slow, tight-binding inhibitor of class I HDAC, including HDAC 1, 2, and 3 with IC50 values of 150 nM , 760nM, and 370 nM, respectively. It demonst...

Reference Reading


1.Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.
Markozashvili D1, Pichugin A2, Barat A1, Camara-Clayette V3, Vasilyeva NV4, Lelièvre H5, Kraus-Berthier L5, Depil S5, Ribrag V3, Vassetzky Y6. Gene. 2016 Apr 15;580(2):134-43. doi: 10.1016/j.gene.2016.01.017. Epub 2016 Jan 13.
Mantle cell lymphoma (MCL) is a rare lymphoma caused by the t(11:14) juxtaposing the cyclin D1 (CCND1) locus on chromosome 11 and the immunoglobulin heavy chain (IgH) locus on chromosome 14. Several new treatments are proposed for MCL, including histone deacetylase inhibitors (HDACi). We have studied gene expression and chromatin organization in the translocated 11q13 locus in MCL cells as compared to lymphoblastoid cell lines as well as the effect of HDACi abexinostat on chromatin organization and gene expression in the 11q13 locus. We have identified a cluster of genes overexpressed in the translocation region on chromosome 11 in MCL cells. Abexinostat provokes a genome-wide disaggregation of heterochromatin. The genes upregulated after the t(11;14) translocation react to the HDACi treatment by increasing their expression, but their gene promoters do not show significant alterations in H3K9Ac and H3K9me2 levels in abexinostat-treated cells.
2.A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.
Evens AM1, Balasubramanian S2, Vose JM3, Harb W4, Gordon LI5, Langdon R6, Sprague J7, Sirisawad M2, Mani C2, Yue J2, Luan Y2, Horton S2, Graef T2, Bartlett NL8. Clin Cancer Res. 2016 Mar 1;22(5):1059-66. doi: 10.1158/1078-0432.CCR-15-0624. Epub 2015 Oct 19.
PURPOSE: Additional targeted therapeutics are needed for the treatment of lymphoma. Abexinostat is an oral pan-histone deacetylase inhibitor (HDACi) displaying potent activity in preclinical models. We conducted a multicenter phase I/II study (N = 55) with single-agent abexinostat in relapsed/refractory lymphoma.
3.Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
Morschhauser F1, Terriou L, Coiffier B, Bachy E, Varga A, Kloos I, Lelièvre H, Sarry AL, Depil S, Ribrag V. Invest New Drugs. 2015 Apr;33(2):423-31. doi: 10.1007/s10637-015-0206-x. Epub 2015 Jan 21.
Background We determined the safety, pharmacokinetics, pharmacodynamics, and antitumour activity of abexinostat in B-cell lymphoma or chronic lymphocytic leukaemia. Patients and methods Thirty-five patients received oral abexinostat 30, 45, or 60 mg/m(2) bid in a 3 + 3 design in three 21-day schedules: 14 days on treatment in schedule 1 (D1-14); 10 days in schedule 2 (D1-5 and D8-12); and 12 days in schedule 3 (D1-4, D8-11, and D15-18). Safety, tumour response, plasma concentration, and histone H3 acetylation were measured. Results Two dose-limiting toxicities occurred in each schedule (one grade 3 febrile neutropenia; five grade 4 thrombocytopenia) at 60 mg/m(2) bid (maximal tolerated dose). The recommended dose was 45 mg/m(2) bid; schedule 1 was considered optimal. Non-haematological drug-related toxicities included grade 1 or 2 diarrhoea (43%), nausea (23%), and vomiting (11%); haematological toxicities included thrombocytopenia (31% grade 3, and 26% grade 4), which remained manageable and reversible on withdrawal.